Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.
Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49.
Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by symmetric arthritis leading to progressive erosion of cartilage and bone. Psoriatic arthritis and ankylosing spondylitis are also inflammatory arthritides that belong to the spondyloarthritides. Disease-modifying anti-rheumatic drugs and biologic therapies including anti-TNF agents are used in their treatment. The TNF antagonists have shown rapid and sustained therapeutic responses. However, a substantial number of patients fail to respond to anti-TNF agents or experience side effects. Golimumab is a human monoclonal antibody to TNF-α requiring less frequent administration compared with current anti-TNF products. Various trials have shown promising results in terms of efficacy and safety in methotrexate-naive and -resistant patients with RA as well as in patients previously treated with other anti-TNF agents. The efficacy of golimumab has also been demonstrated in patients with psoriatic arthritis and ankylosing spondylitis.
类风湿关节炎（RA）是一种慢性炎症性全身性疾病，其特征为对称性关节炎，导致软骨和骨的进行性侵蚀。银屑病关节炎和强直性脊柱炎也是炎症性关节炎，属于脊柱关节炎。疾病修饰抗风湿药物和生物疗法，包括抗 TNF 制剂，用于治疗。TNF 拮抗剂已显示出快速和持续的治疗反应。然而，相当数量的患者对 TNF 拮抗剂无反应或出现副作用。与目前的抗 TNF 产品相比，戈利木单抗是一种针对 TNF-α 的人源单克隆抗体，需要更频繁的给药。各种试验表明，戈利木单抗在甲氨蝶呤初治和耐药的 RA 患者以及以前用其他抗 TNF 药物治疗的患者中具有良好的疗效和安全性。戈利木单抗在银屑病关节炎和强直性脊柱炎患者中也显示出疗效。
